***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Two anticoagulant regimens , similar except for the timing of warfarin therapy , were compared in patients with clinical ly submassive venous thromboembolism ( VTE ) .  Warfarin was begun after 7 days of continuous intravenous heparin infusion in group L ( 127 patients ) or within 3 days ( average 1 day ) of starting heparin in group S ( 139 patients ) , with similar outcomes . The frequency of symptomatic VTE recurrence during the hospital stay was 4.7 % in group L and 3.6 % in group S , and that of symptomless new perfusion defects 8.5 % in group L and 3.9 % in group S. On routine iodine-125-fibrinogen leg scanning of patients presenting with distal thrombosis ( in the calf , popliteal , or distal femoral veins ) 3.6 % of group S but no group L patients had symptomless proximal extension . The incidence of bleeding was similar with both regimens . Outpatient follow-up showed no excess recurrent VTE in either treatment group . Early warfarin treatment significantly shortened hospital stay by an average of 3.9 days ( 30 % ) in patients admitted solely because of VTE BACKGROUND Patients with acute proximal deep-vein thrombosis are usually treated first in the hospital with intravenous st and ard ( unfractionated ) heparin . However , the longer plasma half-life , better bioavailability after subcutaneous administration , and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use . We compared these two approaches . METHODS Patients with acute proximal deep-vein thrombosis were r and omly assigned to receive either intravenous st and ard heparin in the hospital ( 253 patients ) or low-molecular-weight heparin ( 1 mg of enoxaparin per kilogram of body weight subcutaneously twice daily ) administered primarily at home ( 247 patients ) . The study design allowed out patients taking low-molecular-weight heparin  to go home immediately and hospitalized patients taking low-molecular-weight heparin to be discharged early . All the patients received warfarin starting on the second day . RESULTS Thirteen of the 247 patients receiving low-molecular-weight heparin  ( 5.3 percent ) had recurrent thromboembolism , as compared with 17 of the 253 patients receiving st and ard heparin ( 6.7 percent ; P=0.57 ; absolute difference , 1.4 percentage points ; 95 percent confidence interval , -3.0 to 5.7 ) . Five patients receiving low-molecular-weight heparin had major bleeding , as compared with three patients receiving st and ard heparin . After r and omization , the patients who received low-molecular-weight heparin spent a mean of 1.1 days in the hospital , as compared with 6.5 days for the st and ard-heparin group ; 120 patients in the low-molecular-weight- heparin group did not need to be hospitalized at all . CONCLUSIONS Low-molecular-weight heparin can be used safely and effectively to treat patients with proximal deep-vein thrombosis at home Intravenous heparin followed by oral anticoagulant therapy ( e. g. with coumarin ) is still the most widely used treatment for  deep venous thromboembolism .  Self-administered subcutaneous injections of heparin have been thought of as a promising alternative to coumarin , but the high doses required for ongoing prophylaxis have raised concerns about the possible development of bone disease . Certainly , long-term heparin therapy has been reported to cause osteoporosis in both laboratory animals and humans . This study aim ed to compare the efficacy and safety of unfractionated ( UF ) heparin with that of a low molecular weight heparin ( Fragmin , Kabi Pharmacia ) in the prevention of recurrent deep venous thrombosis ( DVT ) and pulmonary embolism ( PE ) in a consecutive series of patients with contraindications to coumarin therapy . The patients comprised 40 men and 40 women , aged between 19 and 92 years ( mean age , 68 years ) . They had all previously been diagnosed as having acute DVT and had been treated with conventional doses of heparin while in hospital . All patients had at least one of the following conditions : recent blood loss ( either spontaneous or during admission while receiving heparin therapy ) ; active gastroduodenal ulcer disease ; psychological or physical inability or unwillingness to underst and and accept the need for regular laboratory monitoring during coumarin treatment ; chronic alcoholism ; dementia ; pregnancy ; recent neurosurgery , and pericardial effusion ; or were over 80 years of age . They were r and omly allocated to receive either UF heparin , 10,000 IU s.c . b.d . , or Fragmin , 5000 IU anti-Factor Xa s.c . b.d . , for a period of 3 - 6 months . ( ABSTRACT TRUNCATED AT 250 WORDS BACKGROUND Body weight-adjusted subcutaneous low-molecular-weight heparin ( LMWH ) has been proven to be at least as effective and safe as dose-adjusted intravenous unfractionated heparin ( UFH ) for the treatment of patients with venous thromboembolism . However , body weight-adjusted dosage of low-molecular-weight heparin may be cumbersome and could lead possibly to incorrect dosing . Therefore a fixed LMWH dose , independent of body-weight , might rationalize initial treatment for venous thromboembolism . METHODS Patients with proven proximal deep-vein thrombosis were r and omly assigned to fixed dose subcutaneous LMWH Certoparin ( 8,000 anti-factor Xa U b.i.d . ; 265 patients ) or to adjusted dose i.v . UFH ( 273 patients ) for 12 days . Vitamin K antagonists were started between day 3 and 7 and continued for up to 6 months . The primary outcome measure was a 30 percent or greater improvement in the Marder Score , as revealed by repeated venography on day 12 ( end of the initial treatment ) . The secondary composite outcome measure included death , recurrent venous thromboembolism and major bleeding and was assessed at day 12 and after 6 months by a blinded adjunction committee . RESULTS The Marder score improved by 30 % or more in 30.3 % and 25.0 % of patients assigned to LMWH ( 198 paired venograms ) and UFH ( 192 paired venograms ) , respectively ( 2p = 0.26 ) . At the end of the initial treatment , the composite outcome was observed in 4 of the 265 patients ( 1.5 % ) r and omized to LMWH , as compared with 14 of the 273 patients ( 5.1 % ) r and omized to UFH ( 2p = 0.03 ) . At 6 months these figures were 6.8 % and 12.8 % , respectively ( risk reduction 0.53 , confidence interval 0.31 - 0.90 , 2p = 0.02 ) . CONCLUSION Fixed dose subcutaneous LMWH certoparin is at least as efficacious as UFH in resolving proximal vein thrombosis We performed a prospect i ve , r and omized , double-blind trial in 194 unselected patients to determine the safety and efficacy of low molecular weight heparin ( Fragmin ) compared with st and ard heparin as the initial treatment of acute venous thromboembolism . Ninety-eight patients received continuous intravenous heparin  , and 96 patients received Fragmin for 5 - 10 days . Doses were adjusted to maintain anti-Xa levels between 0.3 and 0.6 unit/ml for patients with a high risk for a bleeding complication and between 0.4 and 0.9 unit/ml for patients with a low risk for bleeding . Treatment was stopped when a therapeutic level of anticoagulation ( International Normalized Ratio greater than 3.5 ) was reached with coumarins . Thirteen patients in the heparin group and 10 patients in the Fragmin group had a major bleeding complication . The incidence of major and minor bleeding complications combined decreased from 48.9 % to 38.5 % ( 95 % confidence interval for the difference , -3.5 % to + 24.2 % ) , corresponding with a relative bleeding risk reduction of 21.2 % . There were no significant differences in efficacy as defined by new high-probability defects on repeat ventilation-perfusion scintigraphy of the lung in 80 patients : six of 46 patients in the heparin group and 3 of 34 patients in the Fragmin group had new defects ( 95 % confidence interval for the difference , -9.4 % to + 17.8 % ) . We conclude that low molecular weight heparin ( Fragmin ) given in adjusted , continuous , and intravenous doses is safe and effective as initial treatment of acute venous thromboembolism compared with heparin . There is a trend in risk reduction for bleeding in favor of low molecular weight heparin , a trend , however , that is smaller than expected compared with animal studies BACKGROUND An intravenous course of st and ard ( unfractionated ) heparin with the dose adjusted to prolong the activated partial-thromboplastin time to a desired length is the st and ard initial in-hospital treatment for patients with deep-vein thrombosis , but fixed-dose subcutaneous low-molecular-weight heparin appears to be as effective and safe . Because the latter treatment can be given on an outpatient basis , we compared the two treatments in symptomatic out patients with proximal-vein thrombosis but no signs of pulmonary embolism . METHODS We r and omly assigned patients to adjusted-dose intravenous st and ard heparin administered in the hospital ( 198 patients ) or fixed-dose subcutaneous low-molecular-weight heparin administered at home , when feasible ( 202 patients ) . We compared the treatments with respect to recurrent venous thromboembolism , major bleeding , quality of life , and costs . RESULTS Seventeen of the 198 patients who received st and ard heparin ( 8.6 percent ) and 14 of the 202 patients who received low-molecular-weight heparin ( 6.9 percent ) had recurrent thromboembolism ( difference , 1.7 percentage points ; 95 percent confidence interval , -3.6 to 6.9 ) . Major bleeding occurred in four patients assigned to st and ard heparin ( 2.0 percent ) and one patient assigned to low-molecular-weight heparin ( 0.5 percent ; difference , 1.5 percentage points ; 95 percent confidence interval , -0.7 to 2.7 ) . Quality of life improved in both groups . Physical activity and social functioning were better in the patients assigned to low-molecular-weight heparin . Among the patients in that group , 35 percent were never admitted to the hospital at all , and 40 percent were discharged early . This treatment was associated with a mean reduction in hospital days of 67 percent , ranging from 29 percent to 86 percent in the various study centers . CONCLUSIONS In patients with proximal-vein thrombosis , treatment with low-molecular-weight heparin at home is feasible , effective , and safe BACKGROUND Enoxaparin , a low-molecular-weight heparin administered to hospitalized patients once or twice daily , has shown efficacy and safety equivalent to unfractionated heparin in the treatment of acute venous thromboembolic disease . Although the cost of either enoxaparin regimen is greater than that of unfractionated heparin , the overall cost of care for each of these 3 treatment strategies is unknown . METHODS A cost minimization analysis of a 3-month , partially blinded , r and omized , controlled efficacy and safety trial of anticoagulant therapy for deep vein thrombosis . Three hundred thirty-nine hospitalized patients with symptomatic lower extremity deep vein thrombosis were r and omly assigned to initial therapy with subcutaneous enoxaparin either once ( n = 112 ) or twice ( n = 123 ) daily , or with dose-adjusted intravenous unfractionated heparin ( n = 104 ) , followed by long-term oral anticoagulant therapy . Estimated 1997 total cost from a third-party payer perspective for the 3-month episode of care was calculated by assigning st and ard unit costs to counts of medical re sources used by each patient in the clinical trial . RESULTS Average total cost for the 3-month episode of care was similar across all 3 treatment regimens : once-daily dose of enoxaparin , $ 12,166 ( 95 % confidence interval [ CI ] , $ 10,744-$13,588 ) ; twice-daily dose of enoxaparin , $ 11,558 ( 95 % CI , $ 10,201-$12,915 ) ; and unfractionated heparin , $ 12,146 ( 95 % CI , $ 10,670-$12,622 ) . Bootstrapped estimates and sensitivity analyses did not significantly change findings . CONCLUSIONS There was no significant difference in the overall cost for the 3-month episode of care for patients treated with either enoxaparin or unfractionated heparin . Additional acquisition costs for anticoagulant medication among patients treated with enoxaparin were offset by savings associated with lower incidence of hospital read 
    Output:
    
REVIEW ER 'S CONCLUSIONS Low molecular weight heparin is at least as effective as unfractionated heparin in preventing recurrent venous thromboembolism , and significantly reduces the occurrence of major haemorrhage during initial treatment and overall mortality at the end of follow-up .